SpeA-Specific Killer Tfh Cell Detection for Recurrent Tonsillitis Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic and treatment methods for recurrent tonsillitis caused by Streptococcus pyogenes are inadequate, leading to significant morbidity and the risk of complications such as acute rheumatic fever and rheumatic heart disease, with a lack of effective tools for early screening and management.

Innovation Solution

The development of methods involving the use of Streptococcal pyrogenic exotoxin A (SpeA) and germinal center T follicular helper cells (Tfh cells) for diagnostic and therapeutic approaches, including vaccine compositions and treatments that modulate immune responses, along with genetic markers like HLA Class II alleles for personalized treatment strategies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional diagnostic and treatment methods are used for recurrent tonsillitis, then treatment can be provided, but early screening capability is insufficient and morbidity remains high

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidearly screening capability

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by developing diagnostic methods that detect SpeA-specific killer Tfh cells before full-blown recurrent tonsillitis episodes occur. The method enables early screening through detection of specific immune cell populations and HLA alleles that predict susceptibility to recurrent infections, allowing intervention before morbidity increases

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces conventional mechanical/cultural diagnostic methods with immunological detection methods. Instead of relying on culture-based diagnostics or clinical symptoms alone, the invention uses flow cytometry and other immunological techniques to detect SpeA-specific killer Tfh cells and HLA Class II alleles, providing more reliable and earlier diagnosis

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If tonsillectomy is performed to treat recurrent tonsillitis, then infection episodes are reduced, but surgical risks and loss of immune function occur

Engineering Contradiction:

Improvereduction of infection episodesVSAvoidsurgical risks and immune function loss

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful presence of SpeA-specific killer Tfh cells (which cause recurrent tonsillitis) into a beneficial diagnostic tool. By detecting these cells and associated HLA alleles, the method identifies patients who would benefit most from preventive vaccination or targeted therapy, avoiding unnecessary tonsillectomies while still protecting high-risk patients

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the approach from surgical removal of tonsils to immunological parameter modulation through vaccination. The SpeA vaccine composition modifies the immune system's response to Streptococcus pyogenes, reducing the pathogenic activity of killer Tfh cells without requiring surgical intervention, thereby maintaining tonsillar immune function while preventing recurrent infections

Inventive Principle:

Principle #35Parameter changes

3Reliability

If SpeA vaccine composition is administered, then immune response to Streptococcus pyogenes is enhanced, but vaccine development complexity increases

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidvaccine composition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by focusing on a specific virulence factor (SpeA) rather than attempting to include all Streptococcus pyogenes antigens in the vaccine. This targeted approach segments the complex bacterial pathogen into its most critical immunogenic component, simplifying vaccine formulation while maintaining high effectiveness against recurrent tonsillitis

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses HLA Class II alleles as intermediaries to identify and target the specific patient population that will benefit most from the SpeA vaccine. By screening for HLA-DQ1*06:02 and HLA-DRB1*01:01 alleles, the vaccine strategy is selectively applied to individuals with killer Tfh cells responsive to SpeA, optimizing effectiveness while managing development complexity

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS11517615B2Diagnosis and treatment of infection involving killer t follicular helper cells, methods of preparation, and uses thereof

Publication Date: 2022.12.06 LA JOLLA INST FOR IMMUNOLOGY

AI summary

Recurrent tonsillitis disease (RT) is a common indication for pediatric tonsillectomy, the most frequent childhood surgery. It is unknown why some children develop RT. The present disclosure demonstrates that RT tonsils exhibit significantly smaller germinal centers than non-RT tonsils, concomitant with a bias against Group A Streptococcus (GAS)-specific germinal center follicular helper CD4+ T cells (GC Tfh), and significantly reduced antibodies to the GAS virulence factor SpeA. The present disclosure also shows a significant immunogenetic component to this disease, with the identification of ‘at risk’ and ‘protective’ HLA alleles for RT. Finally, the present disclosure identifies a new cell type, granzyme B+GC Tfh cells, which are activated by SpeA, are significantly more abundant in RT GC Tfh cells, and have the capacity to kill B cells, thus, providing a window into the immunology and genetics of a classic childhood disease and identifies a new type of pathogenic T cell.